Vericel (VCEL) Change in Receivables (2010 - 2026)
Vericel's (VCEL) quarterly Change in Receivables came in at -$12.3 million in Q1 2026, down 44.54% year-on-year from -$22.1 million in Q1 2025, and down 150.61% quarter-over-quarter from $24.2 million in Q4 2025.
Vericel (VCEL) Change in Receivables (2010 - 2026) Analysis & Trends
Vericel has disclosed Change in Receivables across 16 years of filings, most recently posting -$12.3 million for Q1 2026.
- Change in Receivables for Q1 2026 came in at -$12.3 million, down 44.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.5 million (up 557.13% YoY), and the FY2025 annual result was $23.3 million, up 670.42% from the prior year.
- Change in Receivables came in at -$12.3 million for Q1 2026 at Vericel, down from $24.2 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $24.2 million in Q4 2025 to a low of -$12.3 million in Q1 2026.
- The 5-year median for Change in Receivables is $483000.0 (2024), against an average of $2.1 million.
- Across the five-year window, Change in Receivables sank 4745.0% in 2024 and surged 687.77% in 2025, its largest moves.
- Vericel's Change in Receivables stood at $12.2 million in 2022, then jumped by 52.14% to $18.6 million in 2023, then slumped by 30.77% to $12.9 million in 2024, then jumped by 87.72% to $24.2 million in 2025, then tumbled by 150.61% to -$12.3 million in 2026.
- The last three Change in Receivables figures came in at -$12.3 million (Q1 2026), $24.2 million (Q4 2025), and -$3.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -12.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.25 Mn |
| Mar 31, 2026 | -12.25 Mn |
| Dec 31, 2025 | 24.21 Mn |
| Dec 31, 2025 | 24.21 Mn |
| Sep 30, 2025 | -3.86 Mn |
| Sep 30, 2025 | -3.86 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Jun 30, 2025 | 11.39 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Mar 31, 2025 | -8.48 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Dec 31, 2024 | 12.90 Mn |
| Sep 30, 2024 | 483,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Mar 31, 2024 | -8.42 Mn |
| Dec 31, 2023 | 18.63 Mn |
| Dec 31, 2023 | 18.63 Mn |